Reference
  1. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med, 2021, 384(6):497-511.
  2. Krammer F. SARS-CoV-2 vaccines in development. Nature, 2020, 586(7830):516-27.
  3. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science, 2021, 374(6575):1586-93.
  4. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science, 2003, 300(5626):1763-7.
  5. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res, 2022, 198(105252.
  6. Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett, 2022, 62(128629.
  7. Singh RSP, Toussi SS, Hackman F, et al. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Clin Pharmacol Ther, 2022, 112(1):101-11.
  8. Dal-Ré R, Becker SL, Bottieau E, et al. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect Dis, 2022, 22(8):e231-e8.
  9. Sevrioukova IF, Poulos T L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A, 2010, 107(43):18422-7.
  10. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med, 2022, 386(15):1397-408.
  11. National Medical Products Administration of China. Emergency conditional approval of Pfizer’s COVID-19 therapy:nirmatrelvir tablet/ritonavir tablet combination package (i.e. Paxlovid) importation registration [in Chinese]. Available at: https://www. nmpa. gov. cn/yaowen/ypjgyw/20220212085753142. html. Accessed 27 April 2022.
  12. National Health Commission of the People’s Republic of China. Diagnosis and treatment protocol for COVID-19 (trial version 9) [in Chinese]. Available at: http://www. nhc. gov. cn/cms-search/xxgk/getManuscriptXxgk. htm?id=b74ade1b a4494583805a3d2e40093d88. Accessed 20 June 2022.
  13. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
  14. Kim L, Garg S, O’Halloran A, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis, 2021, 72(9):e206-e14.
  15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China:Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13):1239-42.
  16. Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet, 2022, 399(10340):2011-2.
  17. Drew RJ, O’Donnell S, LeBlanc D, et al. The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2. Diagn Microbiol Infect Dis, 2020, 98(3):115130.
  18. Zhang R, Liang H, Tang J. Negative Conversion Rate of SARS-CoV-2 Infection. JAMA Intern Med, 2021, 181(4):566.
  19. Li H, Gao M, You H, et al. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Clin Infect Dis, 2023, 76(3):e148-e54.
  20. Salvatore PP, Dawson P, Wadhwa A, et al. Epidemiological Correlates of Polymerase Chain Reaction Cycle Threshold Values in the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2021, 72(11):e761-e7.
  21. Rao SN, Manissero D, Steele VR, et al. A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther, 2020, 9(3):573-86.
  22. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022, 612(7941):758-63.
  23. Rodríguez-Grande C, Adán-Jiménez J, Catalán P, et al. Inference of Active Viral Replication in Cases with Sustained Positive Reverse Transcription-PCR Results for SARS-CoV-2. J Clin Microbiol. 2021;59(2):e02277-20.Figure legendsFigure 1 The flow chart of the process used to screen eligible patients. Figure 2 Kaplan-Meier curve of primary outcome for nirmatrelvir-ritonavir recipients versus matched control group Figure 3 Change of RT-PCR Ct value for nirmatrelvir-ritonavir recipients versus matched control group Figure 4 Subgroup analysis of the mean difference of time to PCR negative for nirmatrelvir-ritonavir recipients versus matched control group Figure 5 Subgroup analysis of the mean difference of time to viral clearance for patients with different nirmatrelvir-ritonavir initiation time versus matched control group